Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: smh who wrote (1953)	11/4/2000 9:42:48 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Pretty weird - I'm sure companies like HGSI would be most interested to know that they haven't made the transition to the "post-genomics era." <g> The RSTA discussion was interesting, however. This is definitely one to keep an eye on - I have a starter position. I've heard a little buzz about Athersys, but didn't know it is (allegedly) "one of the most eagerly awaited IPOs in years." It had some recent deals with Elan and MEDX. Web site is: athersys.com Peter

To: smh who wrote (1953)	11/5/2000 1:49:52 PM
From: tuck	Respond to of 52153

smh, This being a Sunday . . . Here's a rerun of the disputed play. RH lumps ABSC in the loser category because it's not making the transition to the post-genomic era with a functional genomics angle. Several days earlier, ABSC announced a deal in a PR from which the following is excerpted: "Under the collaboration, Aurora will employ its proprietary green fluorescent protein (``GFP'') technology and beta-lactamase reporter technology to develop screening platforms for Senomyx and will conduct ultra-high throughput screening using Aurora's instrumentation and a library of about 500,000 compounds. Under the terms of the agreement, Senomyx was granted exclusive rights to use Aurora's functional genomics technology with over 400 of Senomyx's chemosensory gene targets for the discovery of consumer products enhancing taste and olfaction. In addition, Senomyx was granted non-exclusive rights to use Aurora's functional genomics technology with such gene targets for the discovery of therapeutic products." Herring's reporter not doing his homework, or rampant buzz-word slinging by ABSC? You make the call! Like many bold predictions in biotech, this set is likely to include many that will not prove out. The more so if the picks are inappropriate right off the bat. Cheers, Tuck